SCHEMBL4920135

SCHEMBL4920135

Cc1[nH]c(I)c(C#N)c1-c1ccc(C#N)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 5/20 0.41
ALDH1A1 P00352 1/20 0.39
CYP2A6 P11509 1/20 0.39
DHODH Q02127 1/20 0.38
SLC11A2 P49281 1/20 0.37
KIF11 P52732 1/20 0.37
MMP3 P08254 1/20 0.36
PDE9A O76083 3/20 0.35
PDE1C Q14123 1/20 0.35
GAA P10253 2/20 0.35
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
MAPT P10636 1/20 0.35
GRIA2 P42262 1/20 0.35
GRIA4 P48058 1/20 0.35
POLB P06746 1/20 0.35
CYP11B2 P19099 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14154934 0.85 KDM4E (0.36) ALDH1A1PDE9APDE1CGAAMAPT
SCHEMBL4909930 0.84 AR (0.44) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL5364215 0.82 CYP2A6 (0.45) ARALDH1A1CYP2A6SLC11A2KIF11
SCHEMBL4910488 0.78 AR (0.43) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL6469556 0.78 AR (0.40) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL2741353 0.78 AR (0.40) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL4910473 0.76 KMT2A (0.44) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL4911844 0.76 AR (0.40) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL4920250 0.75 PDE9A (0.40) ARALDH1A1CYP2A6DHODHSLC11A2
SCHEMBL4918690 0.75 MEN1 (0.43) ARALDH1A1CYP2A6DHODHSLC11A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
US-20080176906-A1 Substituted Pyrrole Derivative TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-24 US disclosed
EP-1824841-A1 SUBSTITUTED PYRROLE DERIVATIVE Takeda Pharmaceutical Company Limited (JP) 2007-08-29 EP disclosed
WO-2006064944-A1 SUBSTITUTED PYRROLE DERIVATIVE TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2006-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176906-A1 Substituted Pyrrole Derivative AR, NR5A1, MC2R AR 1/4885ALDH1A1 408/4885CYP2A6 104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.